Tango Therapeutics price to book ratio TNGX

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 3.8×
6-year median: 3.2×
Against its 6-year history: 59th; percentile: 0 is its lowest day, 100 its highest
6-year range: 0.6× to 74.0×
Peer median: 6.3×

Tango Therapeutics' price to book ratio is 3.8× as of Oct 23, 2026.

That is above its 6-year median of 3.2×, close to the middle of its last 6 years.

Over that time it ranged from 0.6× in May 2025 to 74.0× in Sep 2021.

The median for 10 large drugmakers of a similar size is 6.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.8×	3.6×	11.6×
2025	7.3×	0.6×	9.2×
2024	1.5×	1.4×	5.1×
2023	3.2×	1.2×	4.7×
2022	2.3×	1.0×	2.6×
2021	2.6×	2.4×	74.0×
2020	48.9×	44.2×	48.9×

Against its peers

Companies in Drug Manufacturers - General nearest Tango Therapeutics' size, closest first, today.

Company	Price to book ratio
TNGXTango Therapeutics	3.8×
ARQTArcutis Biotherapeutics	17.8×
LQDALiquidia	19.6×
INDVIndivior Pharmaceuticals	n/m
OGNOrganon	3.6×
NRIXNurix Therapeutics	2.9×
KNSAKiniksa Pharmaceuticals International	9.2×
LGNDLigand Pharmaceuticals	6.3×
AMRXAmneal Pharmaceuticals	197×
PBHPrestige Consumer Healthcare	1.2×
ALKSAlkermes plc.	4.0×
Peer median	6.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Tango Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.